Filing Details
- Accession Number:
- 0001144204-10-009494
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2010-02-23 12:00:00
- Reporting Period:
- 2010-02-22
- Filing Date:
- 2010-02-23
- Accepted Time:
- 2010-02-23 16:04:43
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1318641 | Cleveland Biolabs Inc | CBLI | Services-Commercial Physical & Biological Research (8731) | 200077155 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1369806 | Michael Fonstein | 73 High Street Buffalo NY 14203 | Ceo, President | Yes | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2010-02-22 | 1,000 | $3.87 | 1,280,200 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2010-02-22 | 200 | $3.88 | 1,280,000 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2010-02-22 | 1,900 | $3.89 | 1,278,100 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2010-02-22 | 1,900 | $3.90 | 1,276,200 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Holdings
| Sec. Name | Sec. Type | Price | Date | Expiration Date | Amount | Remaning Holdings | Nature of Ownership |
|---|---|---|---|---|---|---|---|
| Common Stock | Employee Stock Options (Right to Buy) | $8.36 | 2007-04-06 | 2017-04-05 | 37,500 | 37,500 | Direct |
| Common Stock | Employee Stock Options (Right to Buy) | $4.00 | 2008-02-04 | 2018-02-03 | 137,250 | 174,750 | Direct |
| Expiration Date | Amount | Remaning Holdings | Nature of Ownership |
|---|---|---|---|
| 2017-04-05 | 37,500 | 37,500 | Direct |
| 2018-02-03 | 137,250 | 174,750 | Direct |
Footnotes
- The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan and represent approximately 0.4% of the reporting person's 1,311,200 shares held prior to adoption of the plan. The maximum sales subject to the plan in its entirety represent approximately 4.6% of the reporting person's shares held prior to adoption of the plan. Previous Form 4s filed by this reporting person stated that the reporting person held 1,549,000 shares prior to adoption of this 10b5-1 plan which was incorrect.
Billionaire Hedge Funds
